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another hint towards a functional role of SLC transporter poly-
morphisms for RBV bioavailability and related clinical outcomes.
We agree that these genetic associations in heterogeneous stud-
ies with a limited patient number need further replication to
strengthen the importance of the investigated SNPs.
Interestingly, our colleagues observed that RBV concentra-
tions at week 2 have a predicting value for RBV concentrations
at week 4. Therefore, early RBV serum measurement could help
precocious adjustment of RBV dosage in HCV therapy. Most
recent trials with direct-acting antiviral drugs indicate a
continuous role of RBV in antiviral therapy regimens and further
studies will clearly contribute to optimize RBV dosage. For rou-
tine clinical practice, comparative evaluations of pharmacogenet-
ics versus early pharmacokinetics are rather dispensable in our
opinion as drug level measurement will remain the key for clin-
ical decision-making today. However, genetic studies like ours
and the one of D’Avolio et al. contribute to the molecular under-
standing of pharmacokinetics and may guide the way towards a
personalized HCV treatment strategy in the future.
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Open acces‘‘Wait and see’’ policy for early hepatocellular carcinomaTo the Editor:
We would like to comment on the recent article by Midorikawa
and colleagues [1] about the management of early hepatocellular
carcinoma (HCC). The authors suggest a ‘‘wait and see’’ policy
when these lesions are recognized in a cirrhotic liver since the
difference between the beneﬁt of resection and observation was
negligible in this subgroup of patients. In the authors’ opinion,
only overt HCC should be promptly treated whereas early HCC
lesions should not be submitted to any form of therapy (including
liver resection and percutaneous ablation) because of the treat-
ment-related risks of liver function damage and severe complica-
tions. This clinical scenario parallels that of prostate cancer (PC):
as it happens for small HCC detected during surveillance pro-
grams, more and more small volume tumoral foci are detected
on prostatic biopsy ensuing Prostate Speciﬁc Antigen (PSA)
screening [2]. Nowadays, deferred treatment in patients with
insigniﬁcant disease has been advocated in the belief that radical
prostatectomy is associated with signiﬁcant morbidity and
decrease in the quality of life whereas the majority of men are
not at risk for dying of the disease, and that those who demon-
strate disease progression can be identiﬁed and treated before
the tumor becomes incurable [2]. As a consequence, over the last
decade, active surveillance programs have gained popularity: in
suitable candidates, stringent follow-up protocols including
repeat biopsy are implemented so as to pick-up early tumoral
progression [3]. However, similarities between HCC and PC clin-
ical scenarios end at this point: the two tumors have different
natural histories HCC carrying the worse prognosis and being
superimposed on a chronic disease, which per se affects both
patients’ outcome and the decision as to whether or not to start
a whatsoever form of treatment. This makes the window for cura-
tive therapy much narrower than in patients with PC. We agree
that surgery (including resection and liver transplantation) repre-
sents an undue and costly overtreatment for an early HCC, but
the same is not true for radiofrequency ablation (RFA). In our
opinion, the Midorikawa’s suggestion cannot be entirely sharedJournal of Hepatology 20s under CC BY-NC-ND license.since it relies on a misconception that surgery and local ablation
are equivalent in terms of complications rate and capability of
damaging liver function. To support their assumption they quote
outdated and questionable references. In particular, the authors
cite the article by Llovet et al. [4] where an exceedingly high rate
of neoplastic seeding after RFA was reported. Those results, how-
ever, have been harshly criticized and a subsequent multicenter
survey demonstrated clearly that, using a correct needle with-
drawal technique, the seeding rate was far lower (less than
0.9% out of 1314 patients) and negatively affected only by a pre-
vious biopsy on the treated HCC nodule [5]. The authors seem to
ignore that the worldwide use of RFA for HCC depends especially
on its high efﬁcacy in local control of the disease and lower inva-
siveness and costs when compared to surgery. In addition, there
is recent evidence that RFA and resection offer similar results in
terms of overall survival in case of HCC up to 3 cm emerging in
well compensated cirrhosis [6,7].
One more drawback of an attendant approach for early HCC is
that leaving a patients with an untreated cancer (even if small)
poses other kinds of problems. Back to the parallelism with PC,
the active surveillance is accepted by patients with reluctance
as it is demonstrated by the low rate of enrollment in such proto-
cols (not more than 30% of the suitable candidates) [2]. Several
reasons can explain this ﬁnding: the inability to predict with abso-
lute certainty favorable from unfavorable disease on an individual
basis, the poor predictive markers of progression, and ﬁnally the
difﬁculty of modifying the established standards of care. All these
factors, including the psychological attitude of patients and the
loss of the opportunity for cure during the surveillance period,
should be taken into account in case of an active surveillance
protocol for early HCC as suggested by Midorikawa et al.
It is not surprising that some urological groups are trying to
apply the concept of local ablation in low-risk PC patients [8].
Local therapy might prove to be the middle ground for this sub-
group of men, by combining acceptable cancer treatment with
low morbidity.13 vol. 59 j 631–640 635
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Letters to the Editor
If one considers the high rate of effectiveness in destroying
HCC lesions up to 3 cm with low morbidity and no mortality
[9,10], then RFA is the ideal technique to eradicate a small
tumoral focus (early HCC), minimizing the risk associated with
expectant management.
Thanks to the large experience in local ablation of liver cancer
accumulated over the last three decades, all among hepatologists,
gastroenterologists, and radiologists involved in the management
of patients with HCC, seem to be far ahead along the way urolo-
gists are tempting to pursue. We think that a step backward is
not warranted at this time.
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To the Editor:
Is early hepatocellular carcinoma (HCC) really a life-threatening
disease?
We would like to thank Dr. Francica for his interest in our
recently published article on the marginal survival beneﬁt of sur-
gery for early HCC [1]. Although our data did not refer to the
treatment for early HCC by radiofrequency ablation (RFA), we
had expected their proposal that early HCC patients are good can-
didates for RFA because of its low complication rate and high cur-
ability. Yet, we believe that their point of view is absolutely not
objective owing to the reasons described below.
First, the cirrhotic liver harboring early HCC is in quite a
highly carcinogenic state, and despite complete removal of early
HCCs, most of the patients have second primary HCCs, which
really need to be cured, as shown in Fig. 3B of our article [1]. In
addition to the long lead-time required for early HCC to become
overt HCC, it is not too late if early HCCs are resected or ablated
by RFA at the stage of ‘real’ HCC. Thus, early HCC is not a target
lesion for treatment, but a signaling lesion for a second primary
HCC.
Next, it cannot be determined whether early HCC (small hyp-
ovascular tumors) treated by RFA are actually HCC or not because
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needle biopsy is not usually performed in patients who receive
RFA, as reported by Livraghi et al. [2], in their study, needle biopsy
was performed only in 18.3% of patients. This fact suggests that
good outcomes by RFA might be overestimated because of treat-
ment for precursor lesions of HCC. Actually, an apparently low
neoplastic-seeding rate by RFA in high-volume centers as
described above can be achieved by avoiding needle biopsy. We
therefore do not assume that good outcomes of RFA necessarily
lead to lower morbidity.
Finally, whether RFA for small HCCs is as effective as liver
resection also remains controversial because of the small num-
bers of patients enrolled in randomized controlled trials. One
randomized controlled trial performed by Feng et al. [3] sug-
gested that the outcomes of liver resection and RFA are not sig-
niﬁcantly different in patients with small HCCs. However, their
study group comprised only 168 patients. They concluded that
the result of percutaneous RFA depended on tumor location,
and recommended open or laparoscopic ‘surgery’. It is therefore
difﬁcult to standardize the use of RFA for the treatment of early
HCC. In addition, a Markov model analysis performed by Cho
et al. [4] revealed that overall survival after RFA was identical
to that after liver resection, provided that RFA was followed
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